Correlation Between Conduit Pharmaceuticals and Royalty Management

Can any of the company-specific risk be diversified away by investing in both Conduit Pharmaceuticals and Royalty Management at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Conduit Pharmaceuticals and Royalty Management into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Conduit Pharmaceuticals and Royalty Management Holding, you can compare the effects of market volatilities on Conduit Pharmaceuticals and Royalty Management and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Conduit Pharmaceuticals with a short position of Royalty Management. Check out your portfolio center. Please also check ongoing floating volatility patterns of Conduit Pharmaceuticals and Royalty Management.

Diversification Opportunities for Conduit Pharmaceuticals and Royalty Management

-0.51

Correlation Coefficient

Conduit Pharmaceuticals  Royalty Management

Excellent diversification

The 3 months correlation between Conduit and Royalty is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Conduit Pharmaceuticals and Royalty Management Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Management and Conduit Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Conduit Pharmaceuticals are associated (or correlated) with Royalty Management. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Management has no effect on the direction of Conduit Pharmaceuticals i.e., Conduit Pharmaceuticals and Royalty Management go up and down completely randomly.

Pair Corralation between Conduit Pharmaceuticals and Royalty Management

Considering the 90-day investment horizon Conduit Pharmaceuticals is expected to under-perform the Royalty Management. In addition to that, Conduit Pharmaceuticals is 1.87 times more volatile than Royalty Management Holding. It trades about -0.06 of its total potential returns per unit of risk. Royalty Management Holding is currently generating about 0.0 per unit of volatility. If you would invest  109.00  in Royalty Management Holding on September 15, 2024 and sell it today you would lose (2.00) from holding Royalty Management Holding or give up 1.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Conduit Pharmaceuticals  vs.  Royalty Management Holding

Conduit Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Conduit Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Royalty Management

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Royalty Management Holding are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal fundamental indicators, Royalty Management displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Conduit Pharmaceuticals and Royalty Management

The main advantage of trading using opposite Conduit Pharmaceuticals and Royalty Management positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Conduit Pharmaceuticals position performs unexpectedly, Royalty Management can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Management will offset losses from the drop in Royalty Management's long position.

The idea behind Conduit Pharmaceuticals and Royalty Management Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.